Cargando…

Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors

Olaratumab is a monoclonal antibody that specifically binds to platelet‐derived growth factor receptor alpha (PDGFRα) and blocks receptor activation. We conducted a phase 1 trial to evaluate the safety of olaratumab and determine a recommended dose in combination with three different chemotherapy re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mascarenhas, Leo, Ogawa, Chitose, Laetsch, Theodore W., Weigel, Brenda J., Bishop, Michael W., Krystal, Julie, Borinstein, Scott C., Slotkin, Emily K., Muscal, Jodi A., Hingorani, Pooja, Levy, Donna E., Mo, Gary, Shahir, Ashwin, Wright, Jennifer, DuBois, Steven G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897905/ https://www.ncbi.nlm.nih.gov/pubmed/33474828 http://dx.doi.org/10.1002/cam4.3658

Ejemplares similares

Incidence and Management of Olaratumab Infusion-Related Reactions
por: Van Tine, Brian A., et al.
Publicado: (2019)

Olaratumab’s failure in soft tissue sarcoma
por: Bou Zerdan, Maroun, et al.
Publicado: (2021)

Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC‐3G3) to patients with advanced soft tissue sarcoma
por: Villalobos, Victor M., et al.
Publicado: (2019)

Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer
por: McGuire, William P., et al.
Publicado: (2018)

Developments in the management of advanced soft-tissue sarcoma – olaratumab in context
por: Moroncini, Gianluca, et al.
Publicado: (2018)

Phase I study of olaratumab in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2014)

Olaratumab: A New Strategy in the Treatment of Advanced Soft-Tissue Sarcoma
por: Moore, Donald C., et al.
Publicado: (2018)

Olaratumab administered in two cases of phyllodes tumour of the breast: end of the beginning?
por: Kyriazoglou, Anastasios, et al.
Publicado: (2019)

Spotlight on olaratumab in the treatment of soft-tissue sarcoma: design, development, and place in therapy
por: Davis, Elizabeth J, et al.
Publicado: (2017)

Metastatic Hepatic Epithelioid Hemangioendothelioma Treated with Olaratumab: A Falling Star Rising?
por: Kyriazoglou, Anastasios, et al.
Publicado: (2020)

Cost-Effectiveness of Olaratumab in Combination with Doxorubicin for Patients with Soft Tissue Sarcoma in the United States
por: Zuluaga-Sanchez, Santiago, et al.
Publicado: (2018)

Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland
por: Gennatas, Spyridon, et al.
Publicado: (2020)

Phase 1 study of olaratumab plus doxorubicin in Japanese patients with advanced soft‐tissue sarcoma
por: Yonemori, Kan, et al.
Publicado: (2018)

Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma -a single-Centre experience
por: Striefler, Jana Käthe, et al.
Publicado: (2020)

Randomized Phase 2 Clinical Trial of Olaratumab in Combination with Gemcitabine and Docetaxel in Advanced Soft Tissue Sarcomas
por: Attia, Steven, et al.
Publicado: (2023)

Olaratumab: a platelet-derived growth factor receptor-α-blocking antibody for the treatment of soft tissue sarcoma
por: Pender, Alexandra, et al.
Publicado: (2017)

Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer
por: Mo, Gary, et al.
Publicado: (2017)

Exposure–response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma
por: Jones, Robin L., et al.
Publicado: (2018)

Response to the combination use of pazopanib with olaratumab in a patient with lung-metastatic embryonal rhabdomyosarcoma: a case report
por: Xing, Tuo, et al.
Publicado: (2021)

The Combination of Olaratumab with Doxorubicin and Cisplatinum Regresses a Chemotherapy-Resistant Osteosarcoma in a Patient-Derived Orthotopic Xenograft Mouse Model
por: Higuchi, Takashi, et al.
Publicado: (2019)

Assessment of the platelet-derived growth factor receptor alpha antibody olaratumab in a panel of patient-derived soft tissue sarcoma xenografts
por: Cornillie, Jasmien, et al.
Publicado: (2019)

Results of an Open-label, Phase Ia/b Study of Pembrolizumab plus Olaratumab in Patients with Unresectable, Locally Advanced, or Metastatic Soft-Tissue Sarcoma
por: Schöffski, Patrick, et al.
Publicado: (2023)

The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas
por: DuBois, Steven G., et al.
Publicado: (2018)

A phase II study of a human anti-PDGFRα monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors
por: Wagner, A. J., et al.
Publicado: (2017)

Therapy-related myeloid neoplasms in 109 patients after radiation monotherapy
por: Patel, Anand Ashwin, et al.
Publicado: (2021)

Dual echo gradient echo imaging for simultaneous thermal mapping in cortical bone and soft tissue
por: Ramsay, Elizabeth, et al.
Publicado: (2015)

Prioritization of Novel Agents for Patients with Rhabdomyosarcoma: A Report from the Children’s Oncology Group (COG) New Agents for Rhabdomyosarcoma Task Force
por: Pacenta, Holly L., et al.
Publicado: (2021)

Oxidative and Excitatory Mechanisms of Developmental Neurotoxicity: Transcriptional Profiles for Chlorpyrifos, Diazinon, Dieldrin, and Divalent Nickel in PC12 Cells
por: Slotkin, Theodore A., et al.
Publicado: (2009)

Recent trends in Pediatric Hematology Oncology fellowship match and the workforce impact
por: Moerdler, Scott, et al.
Publicado: (2021)

Durability of pneumatic dilation monotherapy in treatment-naive achalasia patients
por: Javed, Abid T., et al.
Publicado: (2019)

MySQL
por: DuBois, Paul
Publicado: (2013)

MySQL: the definitive guide to using, programming, and administering MySQL4
por: DuBois, Paul
Publicado: (2003)

Transitional Polytherapy: Tricks of the Trade for Monotherapy to Monotherapy AED Conversions
por: Garnett, William R, et al.
Publicado: (2009)

Erythrodysesthesia: An Unusual Complication With Trastuzumab Monotherapy
por: Fontenot, Andee L, et al.
Publicado: (2021)

Age-Related Trajectories of Brain Structure–Function Coupling in Female Roller Derby Athletes
por: Monroe, Derek C., et al.
Publicado: (2021)

Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis
por: Gupta, Vikas, et al.
Publicado: (2023)

Exposure to Organophosphates Reduces the Expression of Neurotrophic Factors in Neonatal Rat Brain Regions: Similarities and Differences in the Effects of Chlorpyrifos and Diazinon on the Fibroblast Growth Factor Superfamily
por: Slotkin, Theodore A., et al.
Publicado: (2007)

Developmental effects of chlorpyrifos extend beyond neurotoxicity: critical periods for immediate and delayed-onset effects on cardiac and hepatic cell signaling.
por: Meyer, Armando, et al.
Publicado: (2004)

Adverse Benzo[a]pyrene Effects on Neurodifferentiation Are Altered by Other Neurotoxicant Coexposures: Interactions with Dexamethasone, Chlorpyrifos, or Nicotine in PC12 Cells
por: Slotkin, Theodore A., et al.
Publicado: (2013)

Emerging novel agents for patients with advanced Ewing sarcoma: a report from the Children’s Oncology Group (COG) New Agents for Ewing Sarcoma Task Force
por: Bailey, Kelly, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_trqs4nbkh4kfekjbc33f1lbura